MK-8353 (also known as SCH900353; SCH-900353) is a novel, potent, selective and orally bioavailable ERK inhibitor with anticancer activity.

Adjudin, formerly known as AF-2364, is a drug which is under development as a potential non-hormonal male contraceptive drug, which acts by blocking the production of sperm in the testes, but without affecting testosterone production.

BAY-885 is a novel, highly potent and selective ERK5/MAPK7 inhibitor with IC50 of 40 nM.

FR-180204 (FR180204) is a novel, potent, selective and ATP-competitive inhibitor of ERK (extracellular signal-regulated kinase) with potential anti-inflammatory activity and has the potential to be used as a new therapy for rheumatoid arthritis.

XMD17-109, a pyrimido-diazepinone analog, is a novel, potent, specific, cell-permeable and ATP-competitive inhibitor of ERK-5 with important biological activity.

ASTX-029(also known as ERK1/2 inhibitor 2) is a highly potent and selective dual-mechanism ERK inhibitor.

XMD8-92 (XMD-8-92) is a novel, potent and highly selective dual inhibitor of BMK1/ERK5 (big mitogen activated protein kinase 1 / extracellular-signal-regulated kinase) with potential antineoplastic activity.

Rineterkib (LTT-462; ERK-IN-1; ERK-IN1), the compound B extracted from WO2018051306A1, is a novel and potent RAF and ERK1/2 inhibitor with anticancer activity.

JWG-071 is a novel and potent chemical probe.

Ravoxertinib hydrochloride (GDC-0994; RG-7842), the hydrochloride salt of Ravoxertinib, is an orally bioavailable inhibitor of extracellular signal-regulated kinase (ERK1/2) being developed as an anticancer drug.